Pfizer Cut By Bear Stearns, Cost Containment Woes
Bear Stearns downgraded Pfizer (PFE) to "peer perform". The bank seems to think that Lipitor will be eaten alive by generics and that Pfizer’s main weapon against this is cost cuts. The move may be premature. Pfizer has committed to…
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Bear Stearns downgraded Pfizer (PFE) to "peer perform". The bank seems to think that Lipitor will be eaten alive by generics and that Pfizer’s main weapon against this is cost cuts.
The move may be premature. Pfizer has committed to putting four new drugs into the field each year between now and 2011.
Pfizer’s cost cuts paired with even modest success with new products could get the company’s earnings moving again. And, the Bear could be wrong.
Douglas A. McIntyre can be reached at [email protected]. He does not own securities in companies that he writes about.
Contact [email protected] for any questions or corrections.

